Drug Profile
Research programme: apoptosis/autophagic cell death stimulants - CleveXel Pharma/Satt Sud Est
Alternative Names: #236; CVXL-0056Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Unknown
- Developer CleveXel Pharma; SATT Sud Est
- Class Nucleosides; Triazoles
- Mechanism of Action Apoptosis stimulants; Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in France (PO)
- 28 Jan 2018 No recent reports of development identified for research development in Acute-myeloid-leukaemia in France (PO)
- 31 Dec 2013 Early research in Acute myeloid leukaemia in France (PO)